drugset / Trial / NCT00190671
A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
This is the phase 2 portion of a phase 1/2 trial, testing the use of pemetrexed and cyclophosphamide in combination for the treatment of advanced breast cancer. A single arm Phase 1 dose finding (establish maximum tolerated dose) study precedes the randomized phase 2 portion.
Timeline
- Start
- 2005-06
- Primary completion
- 2008-03
- Completion
- 2008-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 600 mg/m2 | Intravenous |
| Subject | Pemetrexed | Small molecule | 600 mg/m2 | Intravenous |
| Subject | Pemetrexed | Small molecule | 1800 mg/m2 | Intravenous |